Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Rises By 84.5%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 187,800 shares, an increase of 84.5% from the November 30th total of 101,800 shares. Based on an average trading volume of 6,130,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.3% of the company’s shares are sold short.

Aptose Biosciences Trading Down 3.9 %

Shares of APTO traded down $0.01 during trading hours on Friday, hitting $0.24. The company had a trading volume of 2,424,998 shares, compared to its average volume of 1,790,199. The company has a market capitalization of $14.50 million, a PE ratio of -0.08 and a beta of 1.06. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.68. The company’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.45.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research note on Tuesday, December 10th. StockNews.com started coverage on shares of Aptose Biosciences in a research report on Monday. They set a “hold” rating on the stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.